ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Extramural Office Lists Initiatives For Reinvention

January 13, 1995

NCI Plans to Expand R01 Grant Funding By$48 Million, Increase Other Grants Also

February 16, 1996

Other Agencies Offer Advice; No Money For Oncology Nurse Training

February 24, 1978

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

PI Defends NCI’s National Lung Screening Trial As “Rigorous” Randomized Trial.

November 3, 2006

Clearinghouse Insists On New Dichlorvos Test; CSWG Disagrees

March 24, 1978